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ABSTRACT
Aims/Introduction: We evaluated the efficacy of multifactorial intensive treatment (IT)
on renal outcomes in patients with type 2 diabetes and advanced-stage diabetic kidney
disease (DKD).
Materials and Methods: The Diabetic Nephropathy Remission and Regression Team
Trial in Japan (DNETT-Japan) is a multicenter, open-label, randomized controlled trial with
a 5-year follow-up period. We randomly assigned 164 patients with advanced-stage dia-
betic kidney disease (urinary albumin-to-creatinine ratio ≥300 mg/g creatinine, serum crea-
tinine level 1.2–2.5 mg/dL in men and 1.0–2.5 mg/dL in women) to receive either IT or
conventional treatment. The primary composite outcome was end-stage kidney failure,
doubling of serum creatinine or death from any cause, which was assessed in the inten-
tion-to-treat population.
Results: The IT tended to reduce the risk of primary end-points as compared with conven-
tional treatment, but the difference between treatment groups did not reach the statistically
significant level (hazard ratio 0.69, 95% confidence interval 0.43–1.11; P = 0.13). Meanwhile,
the decrease in serum low-density lipoprotein cholesterol level and the use of statin were
significantly associated with the decrease in primary outcome (hazard ratio 1.14; 95% confi-
dence interval 1.05–1.23, P < 0.001 and hazard ratio 0.53, 95% confidence interval 0.28–0.998,
P < 0.05, respectively). The incidence of adverse events was not different between treatment
groups.
†A complete list of steering committee and investigators in the DNETT-Japan is
provided in the Appendix S1.
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CLINICAL TRIAL
Conclusions: The risk of kidney events tended to decrease by IT, although it was not
statistically significant. Lipid control using statin was associated with a lower risk of adverse
kidney events. Further follow-up study might show the effect of IT in patients with
advanced diabetic kidney disease.
INTRODUCTION
Diabetic kidney disease (DKD) is the leading cause of end-stage
renal failure in developed and developing countries1,2. DKD is
also an important risk for cardiovascular disease3,4. Although
the prognosis of DKD has been improving, effective interven-
tion against the progression to end-stage renal disease (ESRD)
is still required5–7. The Steno 2 study showed that multifactorial
intervention can prevent the progression of DKD in patients
with type 2 diabetes associated with microalbuminuria8–10.
Recently, the Japan Diabetes Optimal Integrated Treatment
study for three major risk factors of cardiovascular diseases (J-
DOIT3) showed that multifactorial intervention prevents the
onset and advancement of early-stage DKD in patients with
Japanese type 2 diabetes as a secondary outcome11. The Dia-
betes Control and Complications Trial/Epidemiology of Dia-
betes Interventions and Complications (DCCT/EDIC) study
showed a significant effect of prior intensive treatment (IT) on
estimated glomerular filtration rate (eGFR) down to a level of
45 mL/min/1.73 m2 in patients with type 1 diabetes12. How-
ever, it has remained unclear that intensified multifactorial
treatment can prevent the progression of advanced-stage DKD
to ESRD. To clarify the efficacy of intensified multifactorial
intervention on the progression of DKD in an advanced stage,
we carried out a clinical study – the Diabetic Nephropathy
Remission and Regression Team Trial in Japan (DNETT-
Japan)13. DNETT-Japan is a multicenter, randomized, open-la-
bel, parallel-group trial to clarify whether intensive multifacto-
rial intervention, including behavioral modifications and
pharmacological intervention, can prevent the progression to
ESRD in patients with type 2 diabetes with overt proteinuria.
As described in the previous study, DNETT-Japan includes two
protocols13. In the present study, we analyzed the results of
protocol B, in which the patients with advanced-stage DKD are
included.
METHODS
Trial design
The trial design was described previously13. Briefly, this study
was a multicenter randomized, open, parallel trial carried out in
Japan (Clinical Trials gov number, NCT00253786). The trial was
approved by the institutional review board at each trial site, and
carried out in accordance with the principles of the Declaration
of Helsinki. All participants were informed fully by the investiga-
tors and gave written informed consent before trial entry. Mem-
bers of the steering committee designed the trial, supervised its
conduct and were responsible for reporting the results.
Patients
In a 2-month screening period, patients with type 2 diabetes
who met the inclusion and exclusion criteria were enrolled in
the trial (Table S1)13. Briefly, Japanese adults aged 20–75 years
with type 2 diabetes, two consecutive urinary albumin-to-crea-
tinine ratio (UACR) of ≥300 mg/g creatinine (first morning
urine) and serum creatinine level of 1.2–2.5 mg/dL (men) or
1.0–2.5 mg/dL (women) were eligible for participation13. Exclu-
sion criteria are described in Table S1.
Procedures
After the 2-month screening period, patients were randomly
assigned by the block method in a 1:1 ratio to the two treatment
groups: the multifactorial IT group and conventional treatment
(CT) group (Table S2)13. The active treatment period was 5 years.
Patients of the IT group were treated and cared by a project
team of a doctor, nurse, dietician and pharmacologist at each
site, and managed to achieve the following predefined treatment
goals13 (Table S2): (i) hemoglobin A1c (HbA1c) <6.2%; (ii) sys-
tolic blood pressure <125 mmHg and diastolic blood pressure
<75 mmHg by inhibitors of renin–angiotensin system: angioten-
sin-converting enzyme inhibitors (ACE-Is) or angiotensin recep-
tor blockers (ARBs); (iii) total cholesterol <180 mg/dL, low-
density lipoprotein (LDL) cholesterol <100 mg/dL and high-
density lipoprotein cholesterol >40 mg/dL; and (iv) total intake
of protein <0.8 g/kg/day, sodium intake <5 g/day and total daily
energy intake <30 kcal/kg/day. Blood pressure was measured in
the sitting position, and if the target blood pressure was not
reached, both ACE-I and ARB were used concomitantly (long-
acting calcium channel blockers were also added, if required). 3-
Hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors
were added if the LDL cholesterol level was ≥100 mg/dL.
Patients in the IT group who smoked were invited to smoking
cessation courses. All patients in the IT group received a multi-
vitamin supplement (Multivitamin; Takeda Pharmaceutical
Company Limited, Tokyo, Japan) daily to avoid vitamin defi-
ciency caused by protein restriction (Table S2).
All patients visited the outpatient of each site every 3 months.
Blood pressure was measured, and blood and urine samples were
collected at each visit. eGFR was calculated using the modified
Modification of Diet in Renal Disease formula for Japanese par-
ticipants14. Laboratory tests of HbA1c, serum creatinine level,
LDL cholesterol level, urinary protein concentration, urinary
albumin concentration and urinary creatinine concentration were
carried out centrally at SRL (Hachioji, Japan). Other laboratory
tests were carried out at each clinical site.
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Trial outcomes
The outcomes were described previously and are shown in
Table S3.13 Briefly, the primary outcome is a composite of end-
stage kidney failure (chronic dialysis or renal transplantation),
doubling of serum creatinine or death. The secondary outcomes
are eGFR, cardiovascular event, progression of retinopathy,
UACR and urinary protein-to-creatinine ratio.
Trial safety monitoring
In the middle of the intervention period, we obtained the infor-
mation regarding intervention-related serious adverse events
from two major clinical trials; The Action to Control Cardio-
vascular Risk in Diabetes (ACCORD) trial15 and The Ongoing
Telmisartan Alone and in Combination with Ramipril Global
Endpoint Trial (ONTARGET)16. In the ACCORD trial, the
intensive-therapy regimen (targeting a HbA1c level of <6.0%)
was discontinued in February 2008 because of the increased
incidence of death in the intensified therapy group than in the
standard therapy group (targeting a HbA1c level from 7.0 to
7.9%). In the present trial, the adverse events related to hypo-
glycemia were assessed by the independent study monitoring
committee in 2008; however, there was no evidence suggesting
a hypoglycemia-related increase in adverse events in the IT
group, and the continuation of the trial was approved by the
independent study monitoring committee. In the ONTARGET,
it was reported that the adverse events including renal dysfunc-
tion were increased by combination therapy with ACE-Is and
ARBs, which raised concerns about the safety of combination
therapy in the present trial. The continuation of this trial was
approved by the independent study monitoring committee in
2008, because an increase of adverse effects related to the com-
bination therapy was not found in the IT group.
Statistical analysis
The procedure of statistical analysis was described previously13.
Briefly, we used the full analysis set (FAS) for the primary effi-
cacy analysis set, and per-protocol set for the secondary efficacy
analysis set, as described previously13. We used the Kaplan–
Meier method to analyze the primary end-point and cardiovas-
cular event. The Cox proportional hazards model was used to
estimate the hazard ratios with 95% confidence intervals in the
event rates. The covariates were sex, age, ACE-I treatment,
baseline UACR and baseline serum creatinine level.
The Kaplan–Meier method was used to compute the cumula-
tive event rate for each defined event for each treatment group.
The overall mean values of risk factors and surrogate kidney out-
comes (eGFR, UACR and urinary protein-to-creatinine ratio)
during follow up were compared between treatment groups by
using the linear mixed effects model including treatment groups,
visit times and their interaction terms. For the adjusted analysis
of surrogate kidney outcomes, baseline values of each outcome
were also added to the relevant liner mixed model.
The frequency of the progression of diabetic retinopathy
and all adverse events during the follow-up period were
compared by using the v2-test. The associations of the risk
factors at baseline or during follow up with the development
of the primary outcome among the patients were estimated
by using the Cox proportional hazards model with time-de-
pendent covariates.
The mean, median and standard deviation for the clinical
test values were calculated at each measurement point13. A
two-sided value of P < 0.05 was considered to be statistically
significant. The SAS statistical software program, version 9.3
(SAS Institute Inc., Cary, NC, USA) was used for the statistical
analysis.
The sample size was determined based on the following con-
siderations: (i) incidence of the primary composite outcome of
40% in the CT group and 25% in the IT group; (ii) two-sided
type I error rate (a) of 0.05; (iii) power of 80%; and (iv) loss-
to-follow-up of 20% in the study period. We calculated a sam-
ple size of 200 subjects for each study group, which would
allow an 80% power to detect differences between groups with
a significance level of <0.05.
RESULTS
From September 2005 through May 2009, a total of 438
patients were screened, of whom 274 were excluded because
they did not meet inclusion and exclusion criteria; 164 under-
went randomization at 65 sites in Japan and were randomly
assigned to IT (n = 80) or CT (n = 84; Figure 1). The mean
follow-up period was 168.4 weeks (standard deviation
88.4 weeks), the median follow-up period was 162.0 weeks (in-
terquartile range 82.1–260.4 weeks). The baseline characteristics
were similar in the two groups (Table 1).
Concomitant drug treatment during the follow-up period
Blood pressure-lowering agents were used for all patients in the
IT group and 97.4% of the patients in the CT group (P = 0.17;
Table S4). ARB was used for 98.6% of the patients in the IT
group and 94.8% of the patients in the CT group (P = 0.20).
The combination therapy of ACE-I and ARB was used for
more patients in the IT group (53.4%) compared with the CT
group (31.3%; P = 0.006).
The use of oral glucose-lowering agents was similar in the
two groups, except for metformin. Metformin was used by
more patients in the IT group (23.9%) compared with the CT
group (7.8%; P = 0.01). The use of insulin was similar in the
two groups. Glucagon-like peptide-1 receptor agonist was used
for five patients in the CT groups.
Blood glucose
Key baseline characteristics were not different in the two groups
(Table 1). At baseline, the mean HbA1c was 7.1% in both
treatment groups (Table 1). The overall mean HbA1c was 6.8
% (95% confidence interval [CI] 6.63–7.09) in the IT group
and 6.94% in the CT group (95% CI 6.72–7.16). There was no
significant difference of HbA1c between the two groups
throughout the observation period (Figure S1a).
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Blood pressure
The mean systolic and diastolic blood pressure was 138.5/
76.9 mmHg in the IT group and 139.5/76.6 mmHg in the CT
group at baseline. There was no significant difference in base-
line blood pressure between the two groups. The overall mean
systolic blood pressure was 132.2 mmHg (95% CI 129.5–134.9)
in the IT group and 132.4 mmHg in the CT group (95% CI
129.9–135.0). The overall mean diastolic blood pressure was
72.2 mmHg (95% CI 70.2–14.2) in the IT group and
72.0 mmHg in the CT group (95% CI 72.2–73.9). There was
no significant difference in blood pressure between the two
groups through the observation period (Figure S1b).
Serum LDL cholesterol concentration
At baseline, the mean LDL cholesterol level was 118.0 mg/dL
in the IT group and 118.9 mg/dL in the CT group. The serum
LDL cholesterol level was not different at baseline between the
two groups. The overall mean serum concentration of LDL
cholesterol was 98.6 mg/dL (95% CI 92.2–105.1) in the IT
group and 104.0 mg/dL in the CT group (95% CI 97.8–110.1).
There was no significant difference of serum LDL cholesterol
level between the two groups through the observation period,
although the mean values of serum LDL cholesterol level were
lower in the IT group (Figure S1c).
Waist circumference
The average waist circumference was 89.6 cm in the IT group
and 91.0 cm in the CT group at baseline. There was no signifi-
cant difference of waist circumference at baseline between the
two groups. The overall mean waist circumference was 91.4 cm
(95% CI 88.4–94.6) in the IT group and 92.3 cm (95% CI
89.5–95.1) in the CT group. There was no significant difference
of waist circumference between two groups through the obser-
vation period (Figure S1d).
Intensive treatment
n = 80
Full Analysis Set
n = 73
Per Protocol Set
n = 59
• No follow-up data 
(n = 7)
• No consent (n = 2)
• No follow-up data 
(n = 2)
Follow-up
Complete (n = 55, 75.3%)
Censored (n = 18, 24.7%)
Withdraw (n = 6)
SAE (n = 6)
Not coming (n = 4)
Others (n = 2)
Conventional treatment
n = 84
Full Analysis Set
n = 80
Per Protocol Set
n = 75
Follow-up
Complete (n = 74, 92.5%)
Censored (n = 6, 7.5%)
Withdraw (n = 2)
SAE (n = 2)
Not coming (n = 2)
Others (n = 2)
Randomization
n = 164
Screening
n = 438
RRT; renal replacement therapy. SAE; severe adverse events.
Figure 1 | Trial profile.
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Smoking status
Smoking status was not different between the two groups. The
frequency of being a current smoker during the follow-up per-
iod was 20.6% in the IT group and 20.0% in CT group.
Primary outcome
IT tended to reduce the risk of primary end-points, con-
sisting of end-stage kidney failure, doubling of serum
creatinine level or death, as compared with CT, but the
difference between the treatment groups did not reach
the statistically significant level (hazard ratio [HR] 0.69,
95% CI 0.43–1.11, P = 0.13; Figure 2). For each compo-
nent of the composite primary outcome, there was no
significant difference between the IT group and the CT
group in both the full analysis set and per-protocol set
(Figure 3).
Table 1 | Baseline characteristics of randomized patients enrolled in the study
Intensive (n = 73) Conventional (n = 80) P-value
Age (years) 56.8 (10.5) 57.6 (8.8) 0.62
Male sex (%) 58.9 55.0 0.63
Duration of diabetes† (years) 15.9 (9.6) 15.1 (8.0) 0.62
Systolic blood pressure (mmHg) 138.5 (19.7) 139.5 (17.6) 0.74
Diastolic blood pressure (mmHg) 76.9 (12.6) 76.6 (10.2) 0.88
Body mass index (kg/m2) 25.5 (4.8) 26.5 (5.4) 0.25
Waist circumstance (cm) 89.6 (11.7) 91.0 (12.7) 0.49
Urinary chemistry
Urinary protein-to-creatinine ratio (g/gCr) 2.0 (1.1–3.8) 2.3 (1.1–4.2) 0.58
Urinary albumin-to-creatinine ratio (mg/gCr) 1,450 (814–2,560) 1,725 (790–2,945) 0.51
Serum chemistry
Urea nitrogen (mg/dL) 28.4 (9.3) 28.4 (9.8) 0.99
Creatinine (mg/dL) 1.6 (0.4) 1.6 (0.4) 0.92
Estimated glomerular filtration rate (mL/min/1.73 m2) 40.1 (11.4) 39.5 (12.2) 0.76
Potassium (mEq/L) 4.6 (0.5) 4.6 (0.6) 0.54
Fasting blood glucose (mg/dL) 133.5 (43.7) 131.7 (47.3) 0.83
Hemoglobin A1c (%) 7.1 (1.4) 7.1 (1.1) 0.92
Total cholesterol (mg/dL) 205.4 (46.9) 207.6 (49) 0.78
HDL cholesterol 54.3 (17) 56 (22.2) 0.61
LDL cholesterol 118 (36.3) 118.9 (36.3) 0.88
Uric acid (mg/dL) 6.9 (1.6) 7 (1.2) 0.77
Total protein (mg/dL) 6.7 (0.6) 6.6 (0.9) 0.16
Albumin (mg/dL) 3.6 (0.6) 0.33
Total bilirubin (mg/dL) 0.5 (0.2) 0.5 (0.1) 0.75
Aspartate aminotransferase (IU/L) 20.7 (6.6) 21.5 (8.2) 0.51
Alanine aminotransferase (IU/L) 17.7 (7.9) 20.3 (11) 0.10
Gamma glutamyl transpeptidase (IU/L) 28.8 (27.2) 36.2 (35.9) 0.18
Lactate dehydrogenase (IU/L) 217.1 (48.7) 228.8 (63.5) 0.23
Hemoglobin (g/dL) 11.6 (1.6) 11.9 (2) 0.46
Other factors
Smoking status (%)
Never smoker 50.7 50.0 0.99
Ex-smoker 28.8 30.0
Current smoker 20.6 20.0
Alcohol intakes (%) 28.8 27.9 0.90
Diabetic retinopathy status (%)
No 7.5 13.2 0.32
Simple 23.9 32.9
Pre-proliferative 20.9 18.4
Proliferative 47.8 35.5
Electrocardiogram abnormalities (%) 15.3 11.3 0.46
Diet therapy (%) 97.3 97.5 0.93
Therapeutic exercise (%) 42.5 42.5 1.00
Values are shown as mean (standard deviation), median (interquartile range) or frequency. †Numbers of participants with available data of duration
of diabetes were 70 participants for the intensive group and 71 participants for the conventional group.
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Secondary outcomes
Cardiovascular events were not changed between IT and CT
(HR 0.56, 95% CI 0.19–1.64 P = 0.29). Progression of diabetic
retinopathy was reached in four patients in the IT group
(5.5%) and seven patients in the CT group (8.8%; P = 0.43).
Overall geometric mean UACR was 986.7 mg/gCr in the IT
group and 1,258.7 g/gCr in the CT group (Figure S2a). Overall
geometric mean urinary protein excretion was 1.47 g/gCr in
the IT group and 1.84 g/gCr in the CT group (Figure S2B).
There was no significant difference of urinary albumin excre-
tion and urinary protein excretion between the two groups.
The overall mean eGFR was 31.1 mL/min/1.73 m2 in the IT
group and 29.2 mL/min/1.73 m2 in the CT group, without sig-
nificant difference (Figure S2c).
Relative risk of outcomes
The relationship between the risk factors at baseline or during
the follow-up period and the development of primary compos-
ite outcome was analyzed using the Cox proportional hazards
model (Table 2). Serum LDL cholesterol and use of statin were
significantly related to the improvement of primary composite
outcome. Combination therapy of ACE-I and ARB did not sig-
nificantly contribute to the outcome. In the baseline risk factors,
UACR (HR 3.00, 95% CI 1.91–4.72, P < 0.0001)) and eGFR
(HR 1.49, 95% CI 1.13–1.96, P = 0.0004) were significantly
related to the primary composite outcome (Table 2).
Adverse events
A total of 154 adverse events, including 39 severe adverse
events, occurred in this trial (Table S5). The incidence of
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Figure 2 | Event-free survival of primary outcomes (dialysis, doubling of
serum creatinine or death) in the randomized patients (full analysis set).
The effects of treatment (hazard ratios with 95% confidence intervals,
and P-values) were estimated by using a Cox proportional hazards
model. CI, confidence interval; HR, hazard ratio.
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Figure 3 | Effects of trial treatment on each outcome in the randomized patients. The effects of treatment (hazard ratios with 95% confidence
intervals and P -values) were estimated by using a Cox proportional hazards model. CI, confidence interval; HR, hazard ratio.
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adverse events was not significantly different between the two
groups (32 in the IT group and 35 in the CT group, P = 0.95).
There was also no significant difference in severe adverse
events, life-threatening adverse events, adverse events requiring
hospital admission and adverse events with physical disability
between the two groups (16 in the IT group and 23 in the CT
group, P = 0.31). As for the event of death, one deceased
patient in the IT group was not reported as an adverse event,
because detailed information of death was not obtained.
DISCUSSION
In the current study, IT tended to reduce the risk of the pri-
mary end-points compared with CT, but the difference between
the treatment groups did not reach the statistically significant
level.
It is clear that blood glucose lowering prevents new onset or
progression of early-stage DKD17–22. Recent meta-analysis has
suggested that intensive glucose control decreases the risk for
surrogate renal outcomes; microalbuminuria and macroalbu-
minuria. However, it has remained unclear whether intensive
glycemic control decreases the risk for renal outcomes, includ-
ing doubling of the serum creatinine concentration, ESRD or
death23. In DNETT-Japan, Cox regression analyses did not
show the superiority of strict blood glucose control. It might be
possible that this trial could not show the efficacy of blood glu-
cose control, because the HbA1c level was controlled <7.0% in
both groups and there was little difference.
Antihypertensive treatment is another substantial strategy for
the therapy of DKD24,25. Several guidelines recommend main-
taining blood pressure <130/80 mmHg in patients with
DKD26,27. In the present trial, the average level of systolic/dias-
tolic blood pressure during the trial period was 132/72 mmHg
in both groups, and there was no difference between the two
groups. Although blood pressure was considerably well man-
aged, it seems to be difficult to achieve the treatment goal in
the IT group. In particular, in the first year, the average level of
blood pressure was elevated in the IT group, because some
patients resistant to antihypertensive drugs were included.
There have been several randomized controlled trials that
showed the strong effect of ARBs and ACE-Is on DKD28–30. In
the current trial, 100% of the patients in the IT group and
97.4% in the CT group were taking renin–angiotensin system
inhibitors. Dual blockade of the renin–angiotensin system did
not significantly contribute to the outcome, whereas the inci-
dence of adverse events was not increased by the dual blockade.
A previous meta-analysis showed that reduction of proteinuria
by ACE-Is and ARB was similar, but their combination was
more effective than either drug alone31. However, in the Ongo-
ing Telmisartan Alone and in Combination with Ramipril Glo-
bal Endpoint Trial (ONTARGET), no renal benefit was shown
by combination treatment, and the risk of hyperkalemia and
acute kidney injury was increased16. In addition, in The Veter-
ans Affairs Nephropathy in Diabetes (VA NEPHRON-D)
study, combination treatment of ACE-I and ARB was
Table 2 | Relationship between the risk factors at baseline or during follow up and the development of the primary end-point among the patients
(full analysis set)
Variables Unit HR (95% CI) P
Risk factors during follow up
Systolic blood pressure (mmHg) per 10 mmHg increment 1.07 (0.93–1.23) 0.35
Serum LDL cholesterol (mg/dL) per 10 mg/dL increment 1.14 (1.05–1.23) 0.001
Serum HDL cholesterol (mg/dL) per 10 mg/dL decrement 0.93 (0.81–1.08) 0.37
HbA1c (%) per 1% increment 0.96 (0.78–1.2) 0.74
Combination of ACE-I + ARB vs no combination of ACE-I + ARB 0.79 (0.46–1.36) 0.4
Statin use vs no statin use 0.53 (0.28–0.998) 0.049
Risk factors at baseline
Age (years) per 5 years older 0.99 (0.85–1.16) 0.93
Men vs women 1.92 (0.99–3.7) 0.05
eGFR (mL/min/1.73 m2) per 10 mL/min/1.73 m2 decrement 1.49 (1.13–1.96) 0.0004
Log transformed UACR (log[mg/gCr]) per 1 log(mg/gCr) increment 3.00 (1.91–4.72) <0.0001
Hemoglobin (g/dL) per 1 g/dL increment 1.02 (0.86–1.21) 0.84
Electrogram abnormalities vs no 0.92 (0.41–2.07) 0.85
Diet therapy vs no 1.05 (0.12–9.02) 0.97
Therapeutic exercise vs no 1.29 (0.74–2.22) 0.37
Current smoker vs no 0.89 (0.43–1.83) 0.75
Alcohol intakes vs no 0.78 (0.4–1.52) 0.47
The model included the risk factors during follow up (systolic blood pressure, serum high-density lipoprotein [HDL] cholesterol, serum low-density
lipoprotein [LDL] cholesterol, hemoglobin A1c [HbA1c], statin use and combined use of angiotensin-converting enzyme inhibitor [ACE-I] and angio-
tensin-receptor blocker [ARB]) and the other risk factors at baseline. eGFR, estimated glomerular filtration rate; UACR, urinary albumin-to-creatinine
ratio.
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associated with an increased risk of adverse events in patients
with DKD32. Combination therapy with ACEIs and ARB seems
not to be beneficial for patients with advanced-stage DKD
compared with monotherapy in the current trial.
Interestingly, a decrease in serum LDL cholesterol level and
use of statin are significantly related to the decrease in pri-
mary composite outcome. Statin treatment reduces the risk
for cardiovascular diseases in patients with chronic kidney dis-
ease, including DKD33. In contrast, it is still controversial
whether lipid-lowering therapy using statins is beneficial for
the development of DKD or not. Several studies and system-
atic reviews showed that statin reduces proteinuria in patients
with DKD, although it is uncertain whether statin prevents
ESRD34–36. Statin treatment is recommended for patients with
DKD in the Kidney Disease Improving Global Outcomes
(KDIGO) clinical practice guideline37. It has been suggested
that pleiotropic effects of statin might be beneficial for DKD
in animal experiments38. It has remained unclear whether
LDL cholesterol lowering per se was effective for the preven-
tion of the primary end-point, because we cannot statistically
analyze the effects of LDL cholesterol lowering independent
from the effect of statin in the present study. The results from
the current trial suggest that LDL cholesterol lowering by sta-
tin was effective on the primary composite outcome in
patients with advanced-stage DKD. Recent clinical trials
showed the protective effect of sodium–glucose cotransporter 2
inhibitors and glucagon-like peptide-1 receptor agonists on
DKD39,40. Sodium–glucose cotransporter 2 inhibitor and gluca-
gon-like peptide-1 receptor agonist are new options to
improve the prognosis of DKD.
The limitations of this trial are as follows. The number of
patients enrolled in the analysis was small and the statistical
power was not sufficient. The rate of continuation of this trial
was lower in the IT group. In addition, the majority of the
patients in the IT group were not able to achieve the prede-
fined treatment goals, and therefore, there was little difference
between two groups. One of the explanations might be that the
patients in both groups were treated by the same doctors, who
are diabetologists or nephrologists at each site. The factor that
contributed to the tendency of decrease in renal events by IT
was unclear. The lower level of serum LDL cholesterol might
have contributed.
In conclusion, there was an overall trend toward a lower risk
of the development of kidney events in the IT group than in
the CT group in the present trial, but the benefit of IT could
not be confirmed statistically. Lipid control by statin was associ-
ated with a lower risk of kidney events in addition to strict
control of blood glucose and blood pressure. Further follow-up
study is required to clarify the efficacy of multifactorial intensi-
fied intervention on delaying progression of DKD to ESRD.
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